Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.

Article  CAS  PubMed  Google Scholar 

Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP. The role of liver-directed therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(5):129–37.

Article  PubMed  PubMed Central  Google Scholar 

Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21(41):11767–76.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Wei X, Liu Y, Cui B. Prognostic significance of distant metastasis location in patients with metastatic colorectal cancers. Int J Clin Exp Med. 2016;9(11):21681–9.

Google Scholar 

Gabriela Chiorean E, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. J Global Oncol. 2020;6:414–38.

Article  Google Scholar 

Swaid F, Tsung A. Current management of liver metastasis from colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(1):12–21.

Article  Google Scholar 

Abedi P, Bayat A, Ghasemzadeh S, Raad M, Pashaiefar H, Ahmadvand M Upregulation of miR-410 is linked with unfavorable prognosis in patients with colorectal cancer. British journal of biomedical science. 2020

Bi F, Wang Q, Dong Q, Wang Y, Zhang L, Zhang J. Circulating tumor DNA in colorectal cancer: opportunities and challenges. Am J Transl Res. 2020;12(3):1044–55.

CAS  PubMed  PubMed Central  Google Scholar 

Chee B, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Zhang L, Ju JH, Price KS, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Van Loon K, Corcoran RB, Parikh AR, Atreya CE. Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectral cancer (mCRC) following curative intent surgery or radiation. J Clin Oncol. 2021;39(15):3562–5.

Google Scholar 

Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci transl Med. 2020;12(524).

Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nature Communications. 2020;11(1).

Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, et al. VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021;11(2):420–33.

Article  CAS  PubMed  Google Scholar 

Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial. Dig Liver Dis. 2021;53(3):318–23.

Article  PubMed  Google Scholar 

Deschamps F, Ronot M, Gelli M, Durand-Labrunie J, Tazdait M, Hollebecque A, et al. Interventional radiology for colorectal liver metastases. Curr Colorectal Cancer Rep. 2020;16(2):29–37. Review of current IR treatments for mCRC.

Article  Google Scholar 

Van Tilborg AAJM, Meijerink MR, Sietses C, Van Waesberghe JHTM, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: A potentially curative intervention. Br J Radiol. 2011;84(1002):556–65.

Article  PubMed  PubMed Central  Google Scholar 

Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017;8(31):51792–9.

Article  PubMed  PubMed Central  Google Scholar 

James T, Hill J, Fahrbach T, Collins Z. Differences in radiation activity between glass and resin 90y microspheres in treating unresectable hepatic cancer. Health Phys. 2017;112(3):300–4.

Article  CAS  PubMed  Google Scholar 

Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiol. 2011;259(3):641–57.

Article  Google Scholar 

Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21(4):294–302.

Article  PubMed  PubMed Central  Google Scholar 

Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses Data Distilled. Radiol Clin North Am. 2015;53(5):973–84.

Article  PubMed  Google Scholar 

Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015;21(21):6518–25.

Article  PubMed  PubMed Central  Google Scholar 

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.

Article  CAS  PubMed  Google Scholar 

Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14(11):1664–9.

Article  PubMed  PubMed Central  Google Scholar 

Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum. 1979;22(6):371–5.

Article  CAS  PubMed  Google Scholar 

Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15(4):335–45. Trial demonstrating glass microspheres safety in unresectable HCC patients with portal vein thrombosis.

Article  PubMed  Google Scholar 

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterol. 2016;151(6):1155-63.e2.

Article  Google Scholar 

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

Article  CAS  PubMed  Google Scholar 

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.

Article  CAS  PubMed  Google Scholar 

Ricke J, Sangro B, Amthauer H, Bargellini I, Bartenstein P, De Toni E, et al. The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the soramic trial palliative cohort. J Hepatol. 2018;68:S102.

Article  Google Scholar 

Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.

Article  PubMed  Google Scholar 

Khatib J, Kainthla R. Optimal use of FOLFOXIRI plus bevacizumab as first-line systemic treatment in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2020;16(4):89–95.

Article  Google Scholar 

Core JM, Frey GT, Sharma A, Bussone ST, Legout JD, McKinney JM, et al. Increasing yttrium-90 dose conformality using proximal radioembolization enabled by distal angiosomal truncation for the treatment of hepatic malignancy. J Vasc Interv Radiol. 2020;31(6):934–42. Use of voxel-based dosimetry in Y90 treatment.

Article  PubMed  Google Scholar 

Morán V, Prieto E, Sancho L, Rodríguez-Fraile M, Soria L, Zubiria A et al. Impact of the dosimetry approach on the resulting 90Y radioembolization planned absorbed doses based on 99mTc-MAA SPECT-CT: is there agreement between dosimetry methods? EJNMMI Physics. 2020;7(1)

Skanjeti A, Magand N, Defez D, Tordo J, Rode A, Manichon AF et al. Selective internal radiation therapy of hepatic tumors: morphologic and functional imaging for voxel-based computer-aided dosimetry. Biomed Pharm. 2020;132.

Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51(8):1206–12.

Article  PubMed  Google Scholar 

Abbott E, Young RS, Hale C, Mitchell K, Falzone N, Vallis KA et al. Stereotactic inverse dose planning after yttrium-90 selective internal radiation therapy in hepatocellular cancer. Adv Rad Oncol. 2021;6(2).

Mok GSP, Dewaraja YK. Recent advances in voxel-based targeted radionuclide therapy dosimetry. Quant Imaging Med Surg. 2021;11(2):483–9.

Article  PubMed  PubMed Central  Google Scholar 

Kafrouni M, Allimant C, Fourcade M, Vauclin S, Delicque J, Ilonca AD, et al. Retrospective voxel-based dosimetry for assessing the ability of the body-surface-area model to predict delivered dose and radioembolization outcome. J Nucl Med. 2018;59(8):1289–95.

Article  CAS  PubMed  Google Scholar 

Have